1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 10
2 Introduction 11
2.1 Deep Brain Stimulators Overview 11
3 Products under Development 12
3.1 Deep Brain Stimulators – Pipeline Products by Stage of Development 12
3.2 Deep Brain Stimulators – Pipeline Products by Territory 13
3.3 Deep Brain Stimulators – Pipeline Products by Regulatory Path 14
3.4 Deep Brain Stimulators – Pipeline Products by Estimated Approval Date 15
3.5 Deep Brain Stimulators – Ongoing Clinical Trials 16
4 Deep Brain Stimulators – Pipeline Products under Development by Companies 17
4.1 Deep Brain Stimulators Companies – Pipeline Products by Stage of Development 17
4.2 Deep Brain Stimulators – Pipeline Products by Stage of Development 19
5 Deep Brain Stimulators Companies and Product Overview 21
5.1 Adaptive Neuromodulation GmbH Company Overview 21
5.1.1 Adaptive Neuromodulation GmbH Pipeline Products & Ongoing Clinical Trials Overview 21
5.2 Aleva Neurotherapeutics SA Company Overview 22
5.2.1 Aleva Neurotherapeutics SA Pipeline Products & Ongoing Clinical Trials Overview 22
5.3 Boston Scientific Corp Company Overview 25
5.3.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 25
5.4 Brainsway Ltd Company Overview 30
5.4.1 Brainsway Ltd Pipeline Products & Ongoing Clinical Trials Overview 30
5.5 Cerene Biomedics, Inc. Company Overview 40
5.5.1 Cerene Biomedics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 40
5.6 Cerevast Therapeutics Inc Company Overview 41
5.6.1 Cerevast Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 41
5.7 Children’s Hospital Boston Company Overview 42
5.7.1 Children’s Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 42
5.8 Cleveland Medical Devices Inc Company Overview 43
5.8.1 Cleveland Medical Devices Inc Pipeline Products & Ongoing Clinical Trials Overview 43
5.9 Clinatec Company Overview 44
5.9.1 Clinatec Pipeline Products & Ongoing Clinical Trials Overview 44
5.10 Deep Brain Innovations, LLC Company Overview 45
5.10.1 Deep Brain Innovations, LLC Pipeline Products & Ongoing Clinical Trials Overview 45
5.11 Duke University Company Overview 50
5.11.1 Duke University Pipeline Products & Ongoing Clinical Trials Overview 50
5.12 Functional Neuromodulation Inc. Company Overview 51
5.12.1 Functional Neuromodulation Inc. Pipeline Products & Ongoing Clinical Trials Overview 51
5.13 Highland Instruments, Inc. Company Overview 53
5.13.1 Highland Instruments, Inc. Pipeline Products & Ongoing Clinical Trials Overview 53
5.14 Massachusetts General Hospital Company Overview 54
5.14.1 Massachusetts General Hospital Pipeline Products & Ongoing Clinical Trials Overview 54
5.15 Massachusetts Institute of Technology Company Overview 56
5.15.1 Massachusetts Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview 56
5.16 Mayo Clinic US Company Overview 57
5.16.1 Mayo Clinic US Pipeline Products & Ongoing Clinical Trials Overview 57
5.17 Medtronic plc Company Overview 58
5.17.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 58
5.18 National Cheng-Kung University Hospital Company Overview 62
5.18.1 National Cheng-Kung University Hospital Pipeline Products & Ongoing Clinical Trials Overview 62
5.19 NeuroPro Technologies Inc Company Overview 63
5.19.1 NeuroPro Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 63
5.20 Neurosigma Inc Company Overview 64
5.20.1 Neurosigma Inc Pipeline Products & Ongoing Clinical Trials Overview 64
5.21 Newronika s.r.l. Company Overview 66
5.21.1 Newronika s.r.l. Pipeline Products & Ongoing Clinical Trials Overview 66
5.22 Nuraleve Inc. Company Overview 67
5.22.1 Nuraleve Inc. Pipeline Products & Ongoing Clinical Trials Overview 67
5.23 Soterix Medical Inc Company Overview 68
5.23.1 Soterix Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 68
5.24 Sree Chitra Tirunal Institute for Medical Sciences & Technology Company Overview 81
5.24.1 Sree Chitra Tirunal Institute for Medical Sciences & Technology Pipeline Products & Ongoing Clinical Trials Overview 81
5.25 St. Jude Medical Inc Company Overview 83
5.25.1 St. Jude Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 83
5.26 SUNY Downstate Medical Center Company Overview 86
5.26.1 SUNY Downstate Medical Center Pipeline Products & Ongoing Clinical Trials Overview 86
5.27 The University of Utah Company Overview 87
5.27.1 The University of Utah Pipeline Products & Ongoing Clinical Trials Overview 87
5.28 University of California Los Angeles Company Overview 89
5.28.1 University of California Los Angeles Pipeline Products & Ongoing Clinical Trials Overview 89
5.29 University of Central Florida Company Overview 91
5.29.1 University of Central Florida Pipeline Products & Ongoing Clinical Trials Overview 91
5.30 University of Illinois Company Overview 93
5.30.1 University of Illinois Pipeline Products & Ongoing Clinical Trials Overview 93
5.31 University of Michigan Company Overview 95
5.31.1 University of Michigan Pipeline Products & Ongoing Clinical Trials Overview 95
5.32 University of Milan Company Overview 96
5.32.1 University of Milan Pipeline Products & Ongoing Clinical Trials Overview 96
5.33 University of Oxford Company Overview 97
5.33.1 University of Oxford Pipeline Products & Ongoing Clinical Trials Overview 97
5.34 University of South Florida Company Overview 98
5.34.1 University of South Florida Pipeline Products & Ongoing Clinical Trials Overview 98
5.35 Wedge Therapeutics Company Overview 99
5.35.1 Wedge Therapeutics Pipeline Products & Ongoing Clinical Trials Overview 99
6 Deep Brain Stimulators- Recent Developments 100
6.1 Nov 28, 2016: Brainsway Reports Continued Financial Growth for Q3 of 2016 100
6.2 Nov 22, 2016: Medtronic Reports Second Quarter Financial Results 100
6.3 Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report 103
6.4 Nov 15, 2016: CEVA to work with Medtronic for distribution facility construction 103
6.5 Nov 01, 2016: Sheppard Pratt Health System Appoints New Chief Financial Officer 104
6.6 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016 104
6.7 Oct 19, 2016: St. Jude Medical Reports Third Quarter 2016 Results 106
6.8 Oct 13, 2016: Baylor College of Medicine researcher and collaborators awarded grant through NIH BRAIN Initiative 107
6.9 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer 108
6.10 Oct 07, 2016: Directional deep brain stimulation for movement disorders now being used 109
6.11 Oct 06, 2016: St. Jude Medical Announces U.S. Launch and First Implant of New Deep Brain Stimulation System and Directional Lead for Patients Suffering from Movement Disorders 110
6.12 Sep 28, 2016: Soterix Medical Launches PainX tDCS Treatment in Canada with Health Canada Approval 110
6.13 Sep 15, 2016: Medtronic Names Mark Ploof Senior Vice President of Global Operations and Business Services 111
6.14 Aug 25, 2016: Medtronic Reports First Quarter Financial Results 112
6.15 Aug 17, 2016: Jersey Shore University Medical Center is First Hospital In New Jersey to Offer Deep Transcranial Magnetic Stimulation (DTMS) 114
6.16 Aug 03, 2016: Deep Transcranial Magnetic Stimulation Enables Controlled Opening of Blood-Brain Barrier 115
6.17 Jul 28, 2016: Boston Scientific Announces Results For Second Quarter 2016 115
6.18 Jul 21, 2016: TGA Hazard Alert On Medtronic Neuromodulation Deep Brain Stimulation system pocket adaptors 117
6.19 Jul 20, 2016: St. Jude Medical Reports Second Quarter 2016 Results 117
6.20 Jul 19, 2016: Deep Brain Stimulation Continues To Show Promise For Patients With Mild Alzheimer’s Disease 119
6.21 Jul 13, 2016: Boston Scientific Elects Yoshiaki Fujimori to Board of Directors 120
6.22 Jun 30, 2016: NuVasive Agrees to Settle Patent Litigation With Medtronic 120
6.23 Jun 16, 2016: TGA Hazard Alert on Medtronic deep brain stimulation therapy DBS Extension models 7483 and 37086 120
6.24 Jun 16, 2016: St. Jude Medical Broadens Treatment Options for Patients Suffering Movement Disorders with the European Launch of New Deep Brain Stimulation System and Directional Lead 121
6.25 Jun 15, 2016: Soterix Medical awarded $2.5M NIH grant to run Phase-2 Efficacy Trial to treat Aphasia after Stroke with HD-tDCS 121
6.26 Jun 08, 2016: Boston Scientific Announces Restructuring Program to Support Long-Term Growth and Innovation 122
6.27 Jun 06, 2016: Medtronic Outlines Future Growth Vision at Investor Day 123
6.28 May 31, 2016: Medtronic Reports Fourth Quarter and Fiscal Year 2016 Financial Results 123
6.29 May 27, 2016: Aleva Neurotherapeutics Raises USD18 Million in Series C Financing Round 126
6.30 May 17, 2016: Soterix Medical, Announces tDCS-LTE Depression Treatment Partnership Program for Clinicians and Medical Centers based on its Non-invasive Neuromodulation Platform 126
6.31 May 04, 2016: Medtronic Welcomes Karen L. Parkhill as Its New Chief Financial Officer 126
6.32 Apr 06, 2016: Medtronic Statement on U.S. Department of Treasury’s Recent Temporary and Proposed Regulations 127
6.33 Apr 04, 2016: Sheppard Pratt Health System Names New President and CEO 128
6.34 Mar 17, 2016: Medtronic Proposes Proxy Access 128
6.35 Mar 01, 2016: Medtronic Reports Third Quarter Financial Results 129
6.36 Feb 19, 2016: Medtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2016 130
6.37 Feb 17, 2016: FDA Approves Medtronic Deep Brain Stimulation for People with Parkinson’s Disease with Recent Onset of Motor Complications 130
6.38 Feb 02, 2016: Clinatec Raises USD10.6 Million in Venture Financing 132
6.39 Feb 01, 2016: Aleva Neurotherapeutics Enters into Agreement with Greatbatch 132
6.40 Feb 01, 2016: Aleva Neurotherapeutics to Raise Funds in Series C Financing 132
6.41 Jan 14, 2016: Soterix Medical Launches PainX tDCS Treatment in EU with CE Approval 132
6.42 Jan 11, 2016: Medtronic Updates Capital Allocation Plans and Fiscal 2016 EPS Guidance 133
6.43 Dec 29, 2015: Soterix Medical Receives CE Mark Approval for 1×1 tDCS Depression Therapy 134
6.44 Dec 14, 2015: The Medtronic Bakken Invitation Award Honors 12 Patients from Around the World for Giving Back 134
6.45 Dec 09, 2015: Medtronic Announces FDA Approval for the Only Full-Body MR Conditional Deep Brain Stimulation Systems 135
7 Appendix 137
7.1 Methodology 137
7.2 About GlobalData 140
7.3 Contact Us 140
7.4 Disclaimer 140